Lancet 2016 Mar 19
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
Related Questions
Does the STAMPEDE trial, showing a survival benefit with the addition of docetaxel to standard treatment, change the standard of care for high risk, n...
New comment by Radiation Oncologist at Cedars-Sinai Medical Center ( July 2, 2019)
I assume that the risk of docetaxel varies with age so to a certain extent age should be incorporated in the risk-benefit discussion and should be included in a structured, sh...
New answer by Radiation Oncologist at Cedars-Sinai Medical Center (April 22, 2016)
Last year, the results of RTOG 0521 were presented at ASCO and showed that adjuvant docetaxel led to a small improvement in overall survival for men with high risk prostate ca...
We are being referred more patients for salvage radiation after this procedure, not sure what the evidence is.
New answer by Radiation Oncologist at University of Utah School of Medicine (March 14, 2017)
It's an important question without randomized data to support an answer. Even this question will evolve as we bring on-board more advanced imaging such as Fluciclovine PET/CT,...
For those of us just transitioning over to hypofractionation, what are reasonable, but conservative, constraints that you use?
New comment by Radiation Oncologist at START Center for Cancer Care ( December 12, 2021)
It seems that there is some agreement around this area. To be clear, I favor doing the CT sim and treatments exactly the same way no matter what the technique is.
So in...
Should it be started at the initial diagnosis of bone mets?
New comment by Medical Oncologist at Stephen B. Strum, MD PC ( September 5, 2018)
An MD cannot use any anti-resorptive agent rationally unless they understand the mechanism of action involved in excessive bone resorption. An activated osteoclast population...
New answer by Medical Oncologist at Duke University School of Medicine (January 23, 2023)
The most recent update from STAMPEDE's abiraterone arm in the M0 N0 very high risk setting was reported here: Attard et al., PMID 34953525 and strongly suggests that abi/ADT f...
In this case, Gleason 5+5 in all cores, clinical T4.
New comment by Medical Oncologist at Bon Secours Saint Mary's Hospital ( October 1, 2019)
Thank you for your detailed response
I was thinking more in terms of cytoteduction prior to radiation as this is a T4 tumor ( hence involving nearby organs) . With poor...
New comment by Medical Oncologist at Virginia Commonwealth University Health System ( August 18, 2020)
Agree with @Andrew J. Armstrong's nice summary. While I am in favor of starting androgen directed therapy without too much delay, there are recent data supporting metastatecto...
Is there a role of EBRT to the prostate with extended fields to cover the retroperitoneal nodes plus ADT (definitive therapy) or would you treat as ca...
New answer by Radiation Oncologist at Texas Oncology Arlington South (December 12, 2021)
I don’t see the logic in treating only the prostate when u have similar disease in the node. If u radiate, radiate all gross disease area if it can be encompassed in a r...
For example, are PET Axumin or PSMA studies being ordered in the upfront setting?
New comment by Radiation Oncologist at University of North Carolina at Chapel Hill ( December 29, 2021)
Fantastic, thanks @Daniel E. Spratt.